The field of cell therapy is rapidly emerging as a priority area for oncology research and drug development. Currently, two chimeric antigen receptor T-cell therapies are approved by the US Food and Drug Administration and other agencies worldwide for two types of hematologic cancers. To facilitate the development of these therapies for patients with life-threatening cancers with limited or no therapeutic options, science- and risk-based approaches will be critical to mitigating and balancing any potential risk associated with either early clinical research or more flexible manufacturing paradigms. Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy convened an expert group of stakeholders to develop specific strategies and proposals for regulatory opportunities to accelerate the development of cell therapies as promising new therapeutics. This meeting took place in Washington, DC on May 17, 2019. As academia and industry expand research efforts and cellular product development pipelines, this report summarizes opportunities to accelerate entry into the clinic for exploratory studies and optimization of cell products through manufacturing improvements for these promising new therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcyt.2020.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
All-in-one microfluidic immunosensing device for rapid and end-to-end determination of salivary biomarkers of cardiovascular diseases.
Biosens Bioelectron
December 2024
School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang, 315200, China. Electronic address:
Routine screening for cardiovascular diseases (CVDs) through point-of-care assays for at-home or community-based testing of salivary biomarkers can significantly improve patient outcomes. However, its translatability has been hindered by a dearth of biosensing devices that streamline assay procedures for rapid biomarker quantitation. To address this challenge through end-to-end engineering, we developed an in-house, all-in-one microfluidic immunosensing device that integrates on-chip vibration-enhanced incubation, magnetic-assisted separation using immune magnetic bead probes, and colorimetric readout via absorbance measurements.
View Article and Find Full Text PDFCancer Organoids as reliable disease models to drive clinical development of novel therapies.
J Exp Clin Cancer Res
December 2024
Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
On September 23-24 (2024) the 6th Workshop IRE on Translational Oncology, titled "Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies," took place at the IRCCS Regina Elena Cancer Institute in Rome. This prominent international conference focused on tumor organoids, bringing together leading experts from around the world.A central challenge in precision oncology is modeling the dynamic tumor ecosystem, which encompasses numerous elements that evolve spatially and temporally.
View Article and Find Full Text PDFA review on polysaccharide-based delivery systems for edible bioactives: pH responsive, controlled release, and emerging applications.
Int J Biol Macromol
December 2024
College of Biosystems Engineering & Food Science, Zhejiang University, Hangzhou 310058, China. Electronic address:
pH changes occur during bodily lesions, presenting an opportunity for leveraging pH-responsive delivery systems as signals for a targeted response. This review explores the design and application of pH-responsive delivery systems based on natural polysaccharides for the controlled release of bioactives. The article examines the development of diverse delivery carriers, including nanoparticles, nanofibers, nanogels, core-shell carriers, hydrogels, emulsions as well as liposomes and their capacity to respond to pH variations, enabling the precise and targeted delivery of bioactives within the human body.
View Article and Find Full Text PDFGallic Acid: A Potent Metabolite Targeting Shikimate Kinase in .
Metabolites
December 2024
Pharmacognosy and Pharmaceutical Chemistry Department, Faculty of Pharmacy, Taibah University, Al Madinah Al Munawarah 30001, Saudi Arabia.
is a highly multidrug-resistant pathogen resistant to almost all classes of antibiotics; new therapeutic strategies against this infectious agent are urgently needed. Shikimate kinase is an enzyme belonging to the shikimate pathway and has become a potential target for drug development. This work describes the search for Food and Drug Administration (FDA)-approved drugs and natural compounds, including gallic acid, that could be repurposed as selective shikimate kinase inhibitors by integrated computational and experimental approaches.
View Article and Find Full Text PDFEvaluating advancements and opportunities in electro-assisted biodehalogenation of emerging halogenated contaminants.
Bioresour Technol
December 2024
State Key Laboratory of Urban Water Resource and Environment, School of Environment, Harbin Institute of Technology, Harbin 150090, China; School of Civil & Environmental Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. Electronic address:
Article Synopsis
- Electro-assisted biodehalogenation (EASB) is a strategy that helps speed up the breakdown of harmful
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!